Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Evidence-based guides for peptide research — goal-specific comparisons, regulatory updates, GLP-1 deep dives, and foundational primers. Independent COA data throughout.
12 peptides removed from Category 2; 7 on the July 23–24 PCAC advisory docket. What the removal means, what the PCAC vote decides, and how to read the timeline.
Peptide comparisons by research goal — mechanisms, evidence levels, and regulatory status.
Two pan-ERR agonist exercise mimetics from the Burris lab: isoform potency, oral bioavailability, mouse-only efficacy data, and why neither has human safety data.
MOTS-c (AMPK/mitochondrial), Epitalon (circadian clock), CJC-1295 & Ipamorelin (GH-axis lipolysis). Mechanisms, key studies, regulatory status.
DSIP, Epitalon, CJC-1295, and Ipamorelin. Circadian and GH-axis mechanisms, evidence levels, PCAC docket status.
Semax, Selank, Dihexa, and P21. BDNF, CREB, and memory-consolidation pathways. Semax is on the PCAC advisory docket.
GHK-Cu, BPC-157, KPV, and TB-500. Wnt pathway activation, angiogenesis, scalp inflammation. Three on the PCAC advisory docket.
BPC-157, TB-500, MOTS-c, and Ipamorelin. Exercise-induced muscle damage, DOMS resolution, mitochondrial biogenesis, and GH-axis protein synthesis. Three on the PCAC docket.
Epitalon, MOTS-c, GHK-Cu, SS-31, DSIP, Humanin, and Foxo4-DRI. Mitochondrial, telomerase, and circadian mechanisms.
CJC-1295, Ipamorelin, MK-677, Sermorelin, GHRP-2, GHRP-6, IGF-1 LR3, and Tesamorelin. GH-axis and IGF-1 pathways.
GHK-Cu, PT-141 (FDA-approved), BPC-157, MOTS-c, Thymosin Alpha-1, and Kisspeptin-10. Skin, sexual health, metabolic, and hormonal research.
GHK-Cu, collagen peptides, Matrixyl, and Argireline. Injectable vs topical comparison, evidence levels, and collagen remodeling mechanisms.
GHK-Cu, BPC-157, TB-500, and Epitalon. Collagen gene regulation, dermal angiogenesis, keratinocyte migration, and telomerase activation. Three on the PCAC advisory docket.
Retatrutide, semaglutide, tirzepatide, and NAD+ — trial data, sourcing guidance, and vendor quality.
Phase 2 TRIUMPH trial weight loss results by dose, week-by-week timeline, body composition data, and comparison vs tirzepatide and semaglutide.
Where research-grade retatrutide comes from while Phase 3 trials run. COA quality signals, vendor red flags, and the Disclosed Labs trust index.
Head-to-head: mechanisms, trial weight-loss data, COA quality across vendors, and pricing. GLP-1 vs GIP/GLP-1 vs triple agonist.
NAD+ injection sources, typical research context, live A/B-grade vendor pricing, and what to verify on a real NAD+ COA.
Primers on what peptides are, how to access them safely, and what to look for in a compounding pharmacy.
What peptides are, how they work, the different categories, and the regulatory landscape. Beginner-friendly overview.
How peptide therapy works, types of peptides by goal, routes of administration, costs, and how to get started with a prescriber.
Honest look at peptide safety — side effects by category, risks of unregulated sources, FDA stance, and how to evaluate research compounds.
PCAB accreditation, 503A vs 503B differences, USP 797/800 compliance, COA transparency, and quality scoring.
Looking for an alternative to Peptide Sciences? Live trust grades for active research peptide vendors ranked by COA quality.
These guides are for educational and research purposes only. Not medical advice, diagnosis, or treatment. Consult a licensed provider.
Disclosed Labs